ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptide… Read more
ScinoPharm Taiwan Ltd (1789) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.002x
Based on the latest financial reports, ScinoPharm Taiwan Ltd (1789) has a cash flow conversion efficiency ratio of 0.002x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$25.20 Million) by net assets (NT$10.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ScinoPharm Taiwan Ltd - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how ScinoPharm Taiwan Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ScinoPharm Taiwan Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ScinoPharm Taiwan Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fibra Inn
MX:FINN13
|
0.022x |
|
TOURISM HLDGS LTD O.N.
F:UCH
|
N/A |
|
Hindustan Foods Limited
NSE:HNDFDS
|
0.105x |
|
Ningbo Shimao Energy Co.Ltd
SHG:605028
|
0.037x |
|
Goody Science & Technology Co Ltd
SHE:002694
|
0.014x |
|
Rukun Raharja Tbk
JK:RAJA
|
0.041x |
|
Hamilton Thorne Ltd
PINK:HTLZF
|
-0.012x |
|
Neo Performance Materials Inc
PINK:NOPMF
|
0.053x |
Annual Cash Flow Conversion Efficiency for ScinoPharm Taiwan Ltd (2007–2024)
The table below shows the annual cash flow conversion efficiency of ScinoPharm Taiwan Ltd from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$10.53 Billion | NT$750.91 Million | 0.071x | +219.91% |
| 2023-12-31 | NT$10.36 Billion | NT$231.13 Million | 0.022x | -69.88% |
| 2022-12-31 | NT$10.45 Billion | NT$773.79 Million | 0.074x | +52.66% |
| 2021-12-31 | NT$10.51 Billion | NT$509.82 Million | 0.049x | -46.03% |
| 2020-12-31 | NT$10.53 Billion | NT$946.31 Million | 0.090x | +16.88% |
| 2019-12-31 | NT$10.26 Billion | NT$788.95 Million | 0.077x | -34.20% |
| 2018-12-31 | NT$10.54 Billion | NT$1.23 Billion | 0.117x | +25.28% |
| 2017-12-31 | NT$10.42 Billion | NT$971.71 Million | 0.093x | -42.70% |
| 2016-12-31 | NT$10.23 Billion | NT$1.67 Billion | 0.163x | +53.63% |
| 2015-12-31 | NT$9.86 Billion | NT$1.04 Billion | 0.106x | +11.90% |
| 2014-12-31 | NT$9.38 Billion | NT$888.29 Million | 0.095x | -2.80% |
| 2013-12-31 | NT$9.64 Billion | NT$939.47 Million | 0.097x | -9.97% |
| 2012-12-31 | NT$9.07 Billion | NT$981.55 Million | 0.108x | -28.44% |
| 2011-12-31 | NT$8.56 Billion | NT$1.29 Billion | 0.151x | -35.46% |
| 2010-12-31 | NT$6.68 Billion | NT$1.56 Billion | 0.234x | -19.27% |
| 2009-12-31 | NT$4.47 Billion | NT$1.30 Billion | 0.290x | -29.06% |
| 2008-12-31 | NT$3.44 Billion | NT$1.41 Billion | 0.409x | +105.43% |
| 2007-12-31 | NT$2.53 Billion | NT$504.50 Million | 0.199x | -- |